Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533350 | 0.79 | IKBKB (0.30) | — | |
| SCHEMBL17011479 | 0.74 | ALDH1A1 (0.40) | PDK2PDK4PGK1KDM4E | |
| SCHEMBL4186011 | 0.72 | GABBR2 (0.43) | — | |
| SCHEMBL27602031 | 0.72 | FOS (0.35) | PDK2PDK4PGK1KDM4E | |
| SCHEMBL6617995 | 0.71 | ALDH1A1 (0.36) | PDK2PDK4KDM4E | |
| SCHEMBL5230508 | 0.71 | EGFR (0.42) | KDM4E | |
| SCHEMBL4770475 | 0.69 | PDK2 (0.30) | PDK2PDK4 | |
| SCHEMBL4832458 | 0.69 | LMNA (0.43) | KDM4E | |
| SCHEMBL6336909 | 0.69 | AURKA (0.45) | — | |
| SCHEMBL4825139 | 0.69 | FOS (0.41) | PGK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1539755-B1 | 6-ALKOXY-PYRIDO-PYRIMIDINES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20070167484-A1 | 6-Alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M | 2007-07-19 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7196097-B2 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060276646-A1 | 6-alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M | 2006-12-07 | — | — | US | disclosed |
| US-7105525-B2 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2006-09-12 | — | — | US | disclosed |
| US-6965030-B2 | 6-alkoxy-pyrido-pyridine | ROCHE PALO ALTO LLC (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20050203300-A1 | 6-Alkoxy-pyrido-pyrimidines | GOLDSTEIN DAVID M (US) | 2005-09-15 | — | — | US | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC | 2004-02-26 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | PDK2 846/4885PDK4 1978/4885PGK1 1769/4885 |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | CYP2B6, CYP2D6, CNR1 | PDK2 2125/4885PDK4 3253/4885PGK1 2179/4885 |
| US-20060276646-A1 | 6-alkoxy-pyrido-pyrimidines | PDXK, PNPO, CYP2D6 | PDK2 482/4885PDK4 796/4885PGK1 683/4885 |
| US-20050203300-A1 | 6-Alkoxy-pyrido-pyrimidines | CCNO, CCNY, PNPO | PDK2 1075/4885PDK4 1253/4885PGK1 2431/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | PDK2 1506/4885PDK4 2262/4885PGK1 1045/4885 |
| US-20070167484-A1 | 6-Alkoxy-pyrido-pyrimidines | CCNO, PNPO, CYP2B6 | PDK2 1206/4885PDK4 1706/4885PGK1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.